



Provider Issue Briefing

CONTRA COSTA
HEALTH PLAN
595 Center Avenue
Suite 100
Martinez, CA 94553
925.313.6000
Date: June 2019

Contra Costa Health Plan Pharmacy and Therapeutics Committee (P&T)

The CCHP P&T committee met on 6/6/2019. Updates from the meeting are outlined below:

****Changes to the PDL will be effective by mid-July 2019****

Updates/Announcements:

a. Changes to Requirements for Prescribing Hepatitis C Medication:

- In the past, access to direct-acting antiviral (DAA) therapy for the treatment of Hepatitis C has been limited to providers with specialized training in the treatment of Hepatitis C (such as gastroenterology, infectious disease, hepatology, etc.). In an effort to expand the availability of Hepatitis C treatment to all county residents, CCHP will now be allowing all providers to prescribe Hepatitis C drugs through the CCHP prior authorization process (there will no longer be a restriction on provider sub-specialty for prescribing Hepatitis C therapy).
- Criteria for prescribing Hepatitis C therapy will still require genotype testing, proper patient screening, and clinical confirmation that the patient has at least a 12 month life expectancy (per APL 18-013). **Preferred agents will be Mavyret, Epclusa, and Zepatier.** Please contact the CCHP pharmacy unit with any questions.

Quick reference table for all changes to the Preferred Drug List (PDL) and/or Prior Authorization (PA) criteria (for full details of each change, please see individual drugs listed below this table):

<u>Changes Made</u>	<u>Drug Name</u>
Created new PA criteria:	Humira CF (adalimumab citrate-free) Veltassa (patiomer) Lokelma (sodium zirconium cyclosilicate)
Modified PA criteria:	Elidel (pimecrolimus)
Added to the CCHP formulary for Commercial and Medi-Cal lines of business:	Benicar (olmesartan) Benicar HCT (olmesartan/HCTZ) Vitamin B-2 (riboflavin)
Added to the CCHP formulary for Commercial line of business only (remains a Medi-Cal carve-out drug):	Abilify (aripiprazole) Subutex (buprenorphine) Suboxone (buprenorphine/naloxone) Videx EC (didanosine) Intelence (etravirine) Edurant (rilpivirine) Tivicay (dolutegravir) Isentress (raltegravir) Biktarvy (bictegravir/emtricitabine/tenofovir) Dovato (dolutegravir/lamivudine) Juluca (dolutegravir/rilpivirine) Delstrigo (doravirine/lamivudine/tenofovir) Symfi/Symfi Lo (efavirenz/lamivudine/tenofovir) Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir) Odefsey (emtricitabine/rilpivirine/tenofovir)

- Creation of new criteria for Humira CF (adalimumab citrate free) injection:

- Criteria for Humira CF (40mg/0.4mL) will require a trial and failure of Humira 40mg/0.8mL (non-citrate free) injection, documentation from the provider stating that the member is having severe injection site pain that is interfering with the member's compliance, and if the indication is appropriate, the member must have tried and failed Enbrel.
- **Creation of new criteria for Veltassa (patiomer) and Lokelma (sodium zirconium cyclosilicate):**
 - Criteria for Veltassa and Lokelma will require a diagnosis of hyperkalemia, documentation from the provider stating that the member is following a low potassium diet, documentation showing that all medications known to cause hyperkalemia have been discontinued, and documentation of a trial and failure, intolerance, or contraindication to sodium polystyrene sulfonate in the previous 6 months or rationale why it cannot be used. Requests for continuation of therapy will be contingent upon demonstration that the member is clinically benefitting from therapy (as evidenced by potassium level returning to normal or a significant decrease from baseline).
- **Modification of criteria for Elidel (pimecrolimus):**
 - Criteria for Elidel will now require a trial and failure, intolerance or relative contraindication to preferred formulary agent Protopic (tacrolimus).
- **Addition of Benicar (olmesartan) and Benicar HCT (olmesartan/HCTZ) to the formulary:**
 - All strengths have been added to the formulary as tier 1 preferred agents for all CCHP members.
- **Addition of Vitamin B-2 (riboflavin) to the formulary:**
 - Riboflavin 100mg and 400mg tablets have been added to the formulary as tier 1 preferred agents for all CCHP members.
- **All of the following drugs have been added to the CCHP formulary for Commercial plan members and remain a carve-out for Medi-Cal members:**
 - Abilify (aripiprazole): 2mg, 5mg, 10mg, 15mg, 20mg, and 30mg tablets
 - Subutex (buprenorphine): 2mg and 8mg SL tablets
 - Suboxone (buprenorphine/naloxone): 2/0.5mg and 8/2mg SL tablets and films
 - Videx EC (didanosine): 125mg, 200mg, 250mg, and 400mg capsules
 - Intelence (etravirine): 100mg tablets
 - Edurant (rilpivirine): 25mg tablets
 - Tivicay (dolutegravir): 10mg, 25mg, and 50mg tablets
 - Isentress (raltegravir): 25mg, 100mg, and 600mg tablets
 - Biktarvy (bictegravir/emtricitabine/tenofovir): 50/200/25mg tablets
 - Dovato (dolutegravir/lamivudine): 50/300mg tablets
 - Juluca (dolutegravir/rilpivirine): 50/25mg tablets
 - Delstrigo (doravirine/lamivudine/tenofovir): 100/300/300mg tablets
 - Symfi (efavirenz/lamivudine/tenofovir): 600/300/300mg tablets
 - Symfi Lo (efavirenz/lamivudine/tenofovir): 400/300/300mg tablets
 - Genvoya (elvitegravir/cobicistat/emtricitavine/tenofovir): 150/150/200/10mg tablets
 - Odefsey (emtricitabine/rilpivirine/tenofovir): 200/25/25mg tablets

There are numerous ways to view the CCHP Preferred Drug List:

CCHP updates the Preferred Drug List (PDL) after each quarterly Pharmacy & Therapeutics Committee meeting. CCHP invites and encourages practitioners to access each update through the following means:

- An interactive searchable formulary is available within Epic (contact the Epic team with any questions related to functionality).
- A printable copy of the CCHP PDL can be found here: <http://cchealth.org/healthplan/pdf/pdl.pdf>
- A searchable copy of the CCHP PDL can be found here: <http://formularynavigator.com/Search.aspx?siteID=MMRREQ3QBC>
- **EPOCRATES – free mobile & online formulary resource**
 - CCHP providers may add the CCHP formulary to their mobile devices using the following steps:
 - Go to www.epocrates.com and click on “My Account” in the top right.



- Sign in with your Epocrates username and password, if needed.
- Click on "Edit Formularies."
- Follow the on screen instructions to select and download formularies or to remove formularies (plan name in Epocrates is Contra Costa Health Plan).
- Update your device, and the formularies on your mobile device will be changed accordingly.

Epocrates mobile is supported on the iOS (iPhone, iTouch, iPad), Android, & BlackBerry platforms

If you have any questions about the installation or use of Epocrates, please contact Epocrates Customer Support at goldsupport@epocrates.com or at (800)230-2150.

Providers may request a copy of CCHP pharmacy management procedures or specific drug PA criteria by contacting the pharmacy unit directly at 925-957-7260 x2, or via the email listed below:

P&T updates and DUR educational bulletins can be viewed online at
<http://cchealth.org/healthplan/provider-pharmacy-therapeutics.php>

Questions and comments may be directed to CCHP Pharmacy by emailing
cchp_pharmacy_director@hsd.cccounty.us
